Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial
Objective Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies. Anecdotal reports and recent preclinical research suggest that cannabinol (CBN), a constituent of Cannabis sativa derived from delta-9-tetrahydrocannabinol, could b…
Background
Insomnia is a sleep disorder characterised by subjective difficulty falling asleep, maintaining sleep and/or achieving restorative sleep, where symptoms persist for 3months and are accomp…